941 Stock Overview
Theraclion SA develops echotherapy solutions using high intensity focused ultrasound system.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Theraclion SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.38 |
| 52 Week High | €0.73 |
| 52 Week Low | €0.38 |
| Beta | 0.055 |
| 1 Month Change | 0% |
| 3 Month Change | -22.86% |
| 1 Year Change | -47.50% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -52.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| 941 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.003% | 1.8% |
| 1Y | -47.5% | -8.3% | 4.2% |
Return vs Industry: 941 underperformed the German Medical Equipment industry which returned -8.3% over the past year.
Return vs Market: 941 underperformed the German Market which returned 4.2% over the past year.
Price Volatility
| 941 volatility | |
|---|---|
| 941 Average Weekly Movement | 2.8% |
| Medical Equipment Industry Average Movement | 4.5% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 941's share price has been volatile over the past 3 months.
Volatility Over Time: 941's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 30 | Martin Deterre | www.theraclion.com |
Theraclion SA develops echotherapy solutions using high intensity focused ultrasound system. It offers SONOVEIN, a robotic solution for non-invasive echotherapy treatment of varicose veins; ECHOPULSE, a robotic and non-invasive solution for echotherapy treatment of thyroid nodules and breast fibroadenoma; and EPack, a disposable that is installed on the device before treatment and protects the patient’s skin and optimizes the image quality. Theraclion SA was founded in 2004 and is based in Malakoff, France.
Theraclion SA Fundamentals Summary
| 941 fundamental statistics | |
|---|---|
| Market cap | €18.59m |
| Earnings (TTM) | -€3.67m |
| Revenue (TTM) | €3.92m |
4.7x
P/S Ratio-5.1x
P/E RatioIs 941 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 941 income statement (TTM) | |
|---|---|
| Revenue | €3.92m |
| Cost of Revenue | €331.00k |
| Gross Profit | €3.59m |
| Other Expenses | €7.26m |
| Earnings | -€3.67m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.081 |
| Gross Margin | 91.55% |
| Net Profit Margin | -93.82% |
| Debt/Equity Ratio | 34.5% |
How did 941 perform over the long term?
See historical performance and comparison